Skip to content
value.today

Bial: peers

Change the peers

Bial beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Bial, Pestana Hotel Group, Grifols, S.A., Amplifon S.p.A., Stevanato Group S.p.A., DiaSorin S.p.A., Laboratorios Farmaceuticos Rovi, S.A., Almirall, S.A.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Bial, Pestana Hotel Group, Grifols, S.A., Amplifon S.p.A., Stevanato Group S.p.A., DiaSorin S.p.A., Laboratorios Farmaceuticos Rovi, S.A., Almirall, S.A. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureBialbase
🇵🇹 PT
Percentile in Healthcare
Percentile in Portugal
Pestana Hotel Group
🇵🇹 PT
Percentile in Healthcare
Percentile in Portugal
Grifols, S.A.
GRF.MC · 🇪🇸 ES
Percentile in Healthcare
Percentile in Spain
Amplifon S.p.A.
AMP.MI · 🇮🇹 IT
Percentile in Healthcare
Percentile in Italy
Stevanato Group S.p.A.
STVN · 🇮🇹 IT
Percentile in Healthcare
Percentile in Italy
DiaSorin S.p.A.
DIA.MI · 🇮🇹 IT
Percentile in Healthcare
Percentile in Italy
Laboratorios Farmaceuticos Rovi, S.A.
ROVI.MC · 🇪🇸 ES
Percentile in Healthcare
Percentile in Spain
Almirall, S.A.
ALM.MC · 🇪🇸 ES
Percentile in Healthcare
Percentile in Spain
Group median
Size
Market cap (Better neither way: ranked highest first)————$7.9 BAug 1, 2026 · Market data1st of 6$7.7 Blast known, Jan 5, 2024 · Market dataLast known value: no current one2nd of 6$6.4 BAug 1, 2026 · Market data3rd of 6$4.3 BAug 1, 2026 · Market data4th of 6$3.6 BAug 1, 2026 · Market data5th of 6$2.0 Blast known, Jan 5, 2024 · Market dataLast known value: no current one6th of 6$5.4 B6 ranked
Revenue (Better neither way: ranked highest first)——$769 MFY2025 · Wikidata7th of 7$8.5 BFY2025 · ESEF1st of 7$2.7 BFY2025 · ESEF2nd of 7$1.3 BFY2025 · SEC4th of 7$1.3 BFY2025 · ESEF3rd of 7$838 MFY2025 · ESEF6th of 7$1.2 BFY2025 · ESEF5th of 7$1.3 B7 ranked
Net income (Higher is better)——$175 MFY2025 · Wikidata2nd of 7$453 MFY2025 · ESEF1st of 7$103 MFY2025 · ESEF6th of 7$158 MFY2025 · SEC5th of 7$175 MFY2025 · ESEF3rd of 7$158 MFY2025 · ESEF4th of 7$52 MFY2025 · ESEF7th of 7$158 M7 ranked
Employees (Better neither way: ranked highest first)————26,314As on 2022 · Profile1st of 511,265As on 2020 · Profile2nd of 56,010December 31, 2025 · Profile3rd of 51,939As on 2022 · Profile4th of 5——1,7732019 · Profile5th of 56,0105 ranked
Growth
Revenue growth (Higher is better)————————+8.7%FY2025 · ESEF3rd of 647th54th+3.6%FY2025 · ESEF5th of 633rd37th+12.0%FY2025 · SEC2nd of 654th71st+5.0%FY2025 · ESEF4th of 637th44th+1.4%FY2025 · ESEF6th of 629th31st+17.1%FY2025 · ESEF1st of 663rd76th+6.8%6 ranked
Revenue growth, 3 years a year (Higher is better)————————————————+9.0%FY2025 · SEConly one with it50th—————————————+9.0%—
Earnings per share growth (Higher is better)————————————-34.5%FY2025 · ESEF5th of 514th16th+23.6%FY2025 · SEC2nd of 567th67th-11.4%FY2025 · ESEF4th of 526th26th+7.3%FY2025 · ESEF3rd of 547th36th+358.4%FY2025 · ESEF1st of 596th99th+7.3%5 ranked
Margins and returns
Gross margin (Higher is better)————————38.0%FY2025 · ESEF2nd of 323rd39th————29.0%FY2025 · SEC3rd of 315th39th64.7%FY2025 · ESEF1st of 359th80th————————38.0%3 ranked
Operating margin (Higher is better)————————16.5%FY2025 · ESEF4th of 684th69th8.2%FY2025 · ESEF5th of 670th48th16.8%FY2025 · SEC3rd of 684th80th19.1%FY2025 · ESEF2nd of 687th83rd25.0%FY2025 · ESEF1st of 692nd84th6.6%FY2025 · ESEF6th of 667th36th16.6%6 ranked
Net margin (Higher is better)————22.8%FY2025 · Wikidata1st of 791st86th5.3%FY2025 · ESEF5th of 770th50th3.8%FY2025 · ESEF7th of 768th38th11.8%FY2025 · SEC4th of 782nd80th13.0%FY2025 · ESEF3rd of 783rd81st18.9%FY2025 · ESEF2nd of 789th88th4.2%FY2025 · ESEF6th of 768th45th11.8%7 ranked
Free cash flow margin (Higher is better)————————10.4%FY2025 · ESEF5th of 672nd72nd15.0%FY2025 · ESEF3rd of 681st77th1.9%FY2025 · SEC6th of 656th20th23.5%FY2025 · ESEF1st of 692nd84th16.4%FY2025 · ESEF2nd of 682nd85th12.6%FY2025 · ESEF4th of 676th74th13.8%6 ranked
Return on equity (Higher is better)————————5.1%FY2025 · ESEF5th of 676th37th8.7%FY2025 · ESEF4th of 679th47th9.8%FY2025 · SEC2nd of 680th55th9.4%FY2025 · ESEF3rd of 680th53rd22.6%FY2025 · ESEF1st of 692nd85th3.2%FY2025 · ESEF6th of 675th24th9.1%6 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)————————16.5×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————40.4×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price23.6×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price22.6×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price——————
Price to sales (Better neither way: ranked highest first)————————0.9×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————4.8×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price3.1×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price4.3×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price——————
Price to book (Better neither way: ranked highest first)————————0.9×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————3.6×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price2.3×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price4.5×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price——————
Free cash flow yield (Higher is better)————————11.2%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————0.4%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price7.3%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price3.8%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price——————
Scorecard
Scorecard (Higher is better)——1 of 1FY2025 · Scorecard1st of 74 of 6FY2025 · Scorecard5th of 73 of 5FY2025 · Scorecard6th of 710 of 12FY2025 · Scorecard3rd of 73 of 5FY2025 · Scorecard6th of 75 of 5FY2025 · Scorecard1st of 74 of 5FY2025 · Scorecard4th of 780% passed7 ranked
Growth checks (Higher is better)————1 of 2FY2025 · Scorecard4th of 61 of 2FY2025 · Scorecard4th of 66 of 6FY2025 · Scorecard1st of 61 of 2FY2025 · Scorecard4th of 62 of 2FY2025 · Scorecard1st of 62 of 2FY2025 · Scorecard1st of 675% passed6 ranked
Profitability checks (Higher is better)——1 of 1FY2025 · Scorecard1st of 72 of 3FY2025 · Scorecard3rd of 72 of 3FY2025 · Scorecard3rd of 73 of 5FY2025 · Scorecard7th of 72 of 3FY2025 · Scorecard3rd of 73 of 3FY2025 · Scorecard1st of 72 of 3FY2025 · Scorecard3rd of 767% passed7 ranked
Financial health checks (Higher is better)————1 of 1FY2025 · Scorecard1st of 2——1 of 1FY2025 · Scorecard1st of 2——————100% passed2 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)————14.9%2026-Q2 · 13F1st of 2——14.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 2——————14.6%2 ranked
Institutions holding (Better neither way: ranked highest first)————1652026-Q2 · 13F1st of 2——1312026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 2——————1482 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)————————-0.7 pp2026-Q2 against 2026-Q1 · 13Fonly one with it——————-0.7 pp—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Bial: How market caps are worked out; Pestana Hotel Group: How market caps are worked out; Grifols, S.A.: How market caps are worked out; Amplifon S.p.A.: How market caps are worked out; Stevanato Group S.p.A.: How market caps are worked out; DiaSorin S.p.A.: How market caps are worked out; Laboratorios Farmaceuticos Rovi, S.A.: How market caps are worked out; Almirall, S.A.: How market caps are worked out.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Bial———
Pestana Hotel Group———
Grifols, S.A.16.5%FY2025
84th percentile in Healthcaremedian -7.7%, 674 companies
69th percentile in Spainmedian 9.2%, 79 companies
Amplifon S.p.A.8.2%FY2025
70th percentile in Healthcaremedian -7.7%, 674 companies
48th percentile in Italymedian 8.8%, 101 companies
Stevanato Group S.p.A.16.8%FY2025
84th percentile in Healthcaremedian -7.7%, 674 companies
80th percentile in Italymedian 8.8%, 101 companies
DiaSorin S.p.A.19.1%FY2025
87th percentile in Healthcaremedian -7.7%, 674 companies
83rd percentile in Italymedian 8.8%, 101 companies
Laboratorios Farmaceuticos Rovi, S.A.25.0%FY2025
92nd percentile in Healthcaremedian -7.7%, 674 companies
84th percentile in Spainmedian 9.2%, 79 companies
Almirall, S.A.6.6%FY2025
67th percentile in Healthcaremedian -7.7%, 674 companies
36th percentile in Spainmedian 9.2%, 79 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$2.1 B$4.2 B$6.4 B$8.5 B202020212022202320242025Grifols, S.A. $8.5 BAmplifon S.p.A. $2.7 BStevanato Group S.p.A. $1.3 BDiaSorin S.p.A. $1.3 BLaboratorios Farmaceuticos Rovi, S.A. $838 MAlmirall, S.A. $1.2 B

Rank in the group

1st2nd3rd4th5th6th7th20192020202320242025Pestana Hotel Group: 7th of 7 in 2025Pestana Hotel GroupGrifols, S.A.: 1st of 2 in 2020Grifols, S.A.: 1st of 2 in 2023Grifols, S.A.: 1st of 6 in 2024Grifols, S.A.: 1st of 7 in 2025Grifols, S.A.Amplifon S.p.A.: 2nd of 6 in 2024Amplifon S.p.A.: 2nd of 7 in 2025Amplifon S.p.A.Stevanato Group S.p.A.: 2nd of 2 in 2019Stevanato Group S.p.A.: 2nd of 2 in 2020Stevanato Group S.p.A.: 2nd of 2 in 2023Stevanato Group S.p.A.: 4th of 6 in 2024Stevanato Group S.p.A.: 4th of 7 in 2025Stevanato Group S.p.A.DiaSorin S.p.A.: 3rd of 6 in 2024DiaSorin S.p.A.: 3rd of 7 in 2025DiaSorin S.p.A.Laboratorios Farmaceuticos Rovi, S.A.: 6th of 6 in 2024Laboratorios Farmaceuticos Rovi, S.A.: 6th of 7 in 2025Laboratorios FarmaceuticosAlmirall, S.A.: 1st of 2 in 2019Almirall, S.A.: 5th of 6 in 2024Almirall, S.A.: 5th of 7 in 2025Almirall, S.A.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearBialPestana Hotel GroupGrifols, S.A.Amplifon S.p.A.Stevanato Group S.p.A.DiaSorin S.p.A.Laboratorios Farmaceuticos Rovi, S.A.Almirall, S.A.
2025—$769 MWD7th$8.5 BESEF1st$2.7 BESEF2nd$1.3 BSEC4th$1.3 BESEF3rd$838 MESEF6th$1.2 BESEF5th
2024——$7.8 BESEF1st$2.6 BESEF2nd$1.2 BSEC4th$1.3 BESEF3rd$827 MESEF6th$1.1 BESEF5th
2023——$7.1 BESEF1st—$1.2 BSEC2nd———
2022————$1.0 BSEC———
2021————$998 MSEC———
2020——$6.1 BWD1st—$755 MSEC2nd———
2019————$601 MSEC2nd——$957 MWD1st

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Bial#

Companies of the same industry first, then the same sector, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Pestana Hotel Group🇵🇹 Portugal
    Same sector: Healthcare · Same country: Portugal · Ratios of the last two fiscal years on file
    revenue $768 M (fiscal 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    In the group
  • Grifols, S.A.GRF.MC · 🇪🇸 Spain
    Same sector: Healthcare (Pharmaceutical) · Same region: Southern Europe · Ratios of the last two fiscal years on file
    Market cap $7.9 B (Aug 1, 2026) · revenue $8.9 B (year to December 2025)
    37 of 100 (industry or sector 25 + country 7 + figures on file 5)
    In the group
  • Amplifon S.p.A.AMP.MI · 🇮🇹 Italy
    Same sector: Healthcare (Medical Instruments) · Same region: Southern Europe · Ratios of the last two fiscal years on file
    Market cap $7.7 B (last known, Jan 5, 2024) · revenue $2.7 B (year to December 2025)
    37 of 100 (industry or sector 25 + country 7 + figures on file 5)
    In the group
  • Stevanato Group S.p.A.STVN · 🇮🇹 Italy
    Same sector: Healthcare (Medical Instruments) · Same region: Southern Europe · Ratios of the last two fiscal years on file
    Market cap $6.4 B (Aug 1, 2026) · revenue $1.3 B (year to December 2025)
    37 of 100 (industry or sector 25 + country 7 + figures on file 5)
    In the group
  • DiaSorin S.p.A.DIA.MI · 🇮🇹 Italy
    Same sector: Healthcare (Diagnostics and Research) · Same region: Southern Europe · Ratios of the last two fiscal years on file
    Market cap $4.3 B (Aug 1, 2026) · revenue $1.4 B (year to December 2025)
    37 of 100 (industry or sector 25 + country 7 + figures on file 5)
    In the group
  • Laboratorios Farmaceuticos Rovi, S.A.ROVI.MC · 🇪🇸 Spain
    Same sector: Healthcare (Biotechnology) · Same region: Southern Europe · Ratios of the last two fiscal years on file
    Market cap $3.6 B (Aug 1, 2026) · revenue $838 M (year to December 2025)
    37 of 100 (industry or sector 25 + country 7 + figures on file 5)
    In the group
  • Almirall, S.A.ALM.MC · 🇪🇸 Spain
    Same sector: Healthcare (Pharmaceutical) · Same region: Southern Europe · Ratios of the last two fiscal years on file
    Market cap $2.0 B (last known, Jan 5, 2024) · revenue $1.2 B (year to December 2025)
    37 of 100 (industry or sector 25 + country 7 + figures on file 5)
    In the group
  • Faes Farma, S.A.FAE.MC · 🇪🇸 Spain
    Same sector: Healthcare (Pharmaceutical) · Same region: Southern Europe · Ratios of the last two fiscal years on file
    Market cap $1.7 B (Aug 1, 2026) · revenue $688 M (year to December 2025)
    37 of 100 (industry or sector 25 + country 7 + figures on file 5)
    + Add
  • EL.En. S.p.A.ELN.MI · 🇮🇹 Italy
    Same sector: Healthcare (Medical Devices) · Same region: Southern Europe · Ratios of the last two fiscal years on file
    Market cap $1.9 B (Aug 1, 2026) · revenue $673 M (year to December 2025)
    37 of 100 (industry or sector 25 + country 7 + figures on file 5)
    + Add
  • Philogen S.p.A.PHIL.MI · 🇮🇹 Italy
    Same sector: Healthcare · Same region: Southern Europe · Ratios of the last two fiscal years on file
    Market cap $934 M (Aug 1, 2026) · revenue $361 M (year to December 2025)
    37 of 100 (industry or sector 25 + country 7 + figures on file 5)
    + Add
  • Pharma Mar, S.A.PHM.MC · 🇪🇸 Spain
    Same sector: Healthcare (Biotechnology) · Same region: Southern Europe · Ratios of the last two fiscal years on file
    Market cap $2.1 B (Aug 1, 2026) · revenue $250 M (year to December 2025)
    37 of 100 (industry or sector 25 + country 7 + figures on file 5)
    + Add
  • Pharmanutra S.p.A.PHN.MI · 🇮🇹 Italy
    Same sector: Healthcare (Pharmaceutical) · Same region: Southern Europe · Ratios of the last two fiscal years on file
    Market cap $593 M (last known, Jan 5, 2024) · revenue $148 M (year to December 2025)
    37 of 100 (industry or sector 25 + country 7 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.